[短期外围门诊超过在对利尿药耐心心力衰竭的有用性. 最初的经验]
Borja Guerrero Cervera1, Raquel López-Vilella2, Ignacio Sánchez Lázaro2
1Servicio de Cardiología, Hospital Universitari i Politècnic La Fe, Valencia, España.
概括
短期外周超 (UF) 有效地管理心力衰竭患者的流体过载,这些患者对利尿剂有抗性. 这种安全的门诊程序有助于减少利尿剂的依赖,并改善关键的健康标志物.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内部医学 内部医学
背景情况:
- 堵塞是心力衰竭的主要症状,经常因尿液抵抗而复杂化.
- 管理这些患者的液体过载是一个重大的临床挑战.
研究的目的:
- 评估短期外周超过 (UF) 的疗效和安全性,用于患有尿素耐药性的心力衰竭患者.
主要方法:
- 对前5名门诊患者的分析,他们接受了为期12小时的外周UF手术,以检测尿素耐药性.
- 在UF之前,患者至少服用了三种口服利尿剂.
主要成果:
- 超过成功减少或允许停用利尿药物.
- 在利尿症 (P=0.035),体重 (P=.0001) 和肌素水平 (P=0.023) 中观察到显著改善.
- 平均提取量为1520±271毫升.
结论:
- 短期外周UF是心力衰竭和利尿剂耐药性的门诊患者的有效和安全的治疗选择.
- UF可以帮助管理液体过载,并可能减少对高剂量利尿剂的依赖.
相关概念视频
Heart Failure Drugs: Diuretics
430
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
430
Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17
Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
Continuous Renal Replacement Therapy
56
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
56
Dialysis
391
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
391
Hemodialysis I: Introduction
72
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
72


